272 related articles for article (PubMed ID: 20843788)
1. Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity.
Li S; Shimono C; Norioka N; Nakano I; Okubo T; Yagi Y; Hayashi M; Sato Y; Fujisaki H; Hattori S; Sugiura N; Kimata K; Sekiguchi K
J Biol Chem; 2010 Nov; 285(47):36645-55. PubMed ID: 20843788
[TBL] [Abstract][Full Text] [Related]
2. Nephronectin binds to heparan sulfate proteoglycans via its MAM domain.
Sato Y; Shimono C; Li S; Nakano I; Norioka N; Sugiura N; Kimata K; Yamada M; Sekiguchi K
Matrix Biol; 2013 Apr; 32(3-4):188-95. PubMed ID: 23357641
[TBL] [Abstract][Full Text] [Related]
3. Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins.
Talts JF; Andac Z; Göhring W; Brancaccio A; Timpl R
EMBO J; 1999 Feb; 18(4):863-70. PubMed ID: 10022829
[TBL] [Abstract][Full Text] [Related]
4. Recombinant domain IV of perlecan binds to nidogens, laminin-nidogen complex, fibronectin, fibulin-2 and heparin.
Hopf M; Göhring W; Kohfeldt E; Yamada Y; Timpl R
Eur J Biochem; 1999 Feb; 259(3):917-25. PubMed ID: 10092882
[TBL] [Abstract][Full Text] [Related]
5. The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans.
Brown JC; Sasaki T; Göhring W; Yamada Y; Timpl R
Eur J Biochem; 1997 Nov; 250(1):39-46. PubMed ID: 9431988
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of glycosaminoglycan modification and of heterotypic interactions of perlecan domain V.
Friedrich MV; Göhring W; Mörgelin M; Brancaccio A; David G; Timpl R
J Mol Biol; 1999 Nov; 294(1):259-70. PubMed ID: 10556044
[TBL] [Abstract][Full Text] [Related]
7. Perlecan inhibits smooth muscle cell adhesion to fibronectin: role of heparan sulfate.
Lundmark K; Tran PK; Kinsella MG; Clowes AW; Wight TN; Hedin U
J Cell Physiol; 2001 Jul; 188(1):67-74. PubMed ID: 11382923
[TBL] [Abstract][Full Text] [Related]
8. Mapping of binding sites for nidogens, fibulin-2, fibronectin and heparin to different IG modules of perlecan.
Hopf M; Göhring W; Mann K; Timpl R
J Mol Biol; 2001 Aug; 311(3):529-41. PubMed ID: 11493006
[TBL] [Abstract][Full Text] [Related]
9. Differential binding of vascular cell-derived proteoglycans (perlecan, biglycan, decorin, and versican) to the beta-amyloid protein of Alzheimer's disease.
Snow AD; Kinsella MG; Parks E; Sekiguchi RT; Miller JD; Kimata K; Wight TN
Arch Biochem Biophys; 1995 Jun; 320(1):84-95. PubMed ID: 7793988
[TBL] [Abstract][Full Text] [Related]
10. The crystal structure of a laminin G-like module reveals the molecular basis of alpha-dystroglycan binding to laminins, perlecan, and agrin.
Hohenester E; Tisi D; Talts JF; Timpl R
Mol Cell; 1999 Nov; 4(5):783-92. PubMed ID: 10619025
[TBL] [Abstract][Full Text] [Related]
11. The leucine-rich repeat protein PRELP binds perlecan and collagens and may function as a basement membrane anchor.
Bengtsson E; Mörgelin M; Sasaki T; Timpl R; Heinegård D; Aspberg A
J Biol Chem; 2002 Apr; 277(17):15061-8. PubMed ID: 11847210
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of glycosaminoglycan modification of perlecan domain I by site-directed mutagenesis changes protease sensitivity and laminin-1 binding activity.
Sasaki T; Costell M; Mann K; Timpl R
FEBS Lett; 1998 Sep; 435(2-3):169-72. PubMed ID: 9762901
[TBL] [Abstract][Full Text] [Related]
13. Site-directed mutagenesis of a putative heparin binding domain of avian lipoprotein lipase.
Berryman DE; Bensadoun A
J Biol Chem; 1993 Feb; 268(5):3272-6. PubMed ID: 8429005
[TBL] [Abstract][Full Text] [Related]
14. Identification of a heparin binding domain in the N-terminal cleavage site of pro-islet amyloid polypeptide. Implications for islet amyloid formation.
Park K; Verchere CB
J Biol Chem; 2001 May; 276(20):16611-6. PubMed ID: 11145957
[TBL] [Abstract][Full Text] [Related]
15. Perlecan is responsible for thrombospondin 1 binding on the cell surface of cultured porcine endothelial cells.
Vischer P; Feitsma K; Schön P; Völker W
Eur J Cell Biol; 1997 Aug; 73(4):332-43. PubMed ID: 9270876
[TBL] [Abstract][Full Text] [Related]
16. The relationship between perlecan and dystroglycan and its implication in the formation of the neuromuscular junction.
Peng HB; Ali AA; Daggett DF; Rauvala H; Hassell JR; Smalheiser NR
Cell Adhes Commun; 1998 Sep; 5(6):475-89. PubMed ID: 9791728
[TBL] [Abstract][Full Text] [Related]
17. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases.
Whitelock JM; Murdoch AD; Iozzo RV; Underwood PA
J Biol Chem; 1996 Apr; 271(17):10079-86. PubMed ID: 8626565
[TBL] [Abstract][Full Text] [Related]
18. Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion.
Reiland J; Sanderson RD; Waguespack M; Barker SA; Long R; Carson DD; Marchetti D
J Biol Chem; 2004 Feb; 279(9):8047-55. PubMed ID: 14630925
[TBL] [Abstract][Full Text] [Related]
19. An interaction between basement membrane and Alzheimer amyloid precursor proteins suggests a role in the pathogenesis of Alzheimer's disease.
Narindrasorasak S; Altman RA; Gonzalez-DeWhitt P; Greenberg BD; Kisilevsky R
Lab Invest; 1995 Mar; 72(3):272-82. PubMed ID: 7898047
[TBL] [Abstract][Full Text] [Related]
20. Endothelial cells interact with the core protein of basement membrane perlecan through beta 1 and beta 3 integrins: an adhesion modulated by glycosaminoglycan.
Hayashi K; Madri JA; Yurchenco PD
J Cell Biol; 1992 Nov; 119(4):945-59. PubMed ID: 1385448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
